TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...
Seeking Alpha

Onity Group targets 13%-15% adjusted ROE for 2026 as it advances record origination growth and repositions MSR portfolio

The company provided 2026 guidance, targeting "an adjusted ROE of 13% to 15%, which includes the impact of the valuation allowance release on increased equity" (CFO O'Neil). O'Neil stated, "We ...
Investing

TransMedics clarifies Q4 tax benefit impact on earnings

ANDOVER, Mass. - TransMedics Group Inc. (NASDAQ:TMDX) provided additional details today regarding a $103.3 million U.S. tax valuation allowance release that affected its fourth quarter 2025 financial ...